Jeremy Grantham's NVS Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 331,032 shares of Novartis AG (NVS) worth $42.45 M, representing 0.12% of the portfolio. First purchased in 2018-Q2, this long-term strategic position has been held for 23 quarters.
Based on 13F filings, Jeremy Grantham has maintained a strategic position in NVS, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2023, adding 1.14 M shares. Largest reduction occurred in Q1 2024, reducing 581,499 shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Novartis (NVS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novartis (NVS) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2018 | +21,762 | New Buy | 21,762 | $67.69 |
| Q3 2018 | -2,678 | Reduce 12.31% | 19,084 | $77.19 |
| Q4 2018 | -7,366 | Reduce 38.60% | 11,718 | $76.89 |
| Q1 2019 | -4,910 | Reduce 41.90% | 6,808 | $86.08 |
| Q2 2019 | -2,308 | Reduce 33.90% | 4,500 | $91.33 |
| Q3 2019 | -4,500 | Sold Out | 0 | $0.00 |
| Q2 2021 | +3,000 | New Buy | 3,000 | $91.33 |
| Q3 2021 | +159,900 | Add 5330.00% | 162,900 | $81.78 |
| Q4 2021 | +32,800 | Add 20.14% | 195,700 | $87.47 |
| Q1 2022 | -192,200 | Reduce 98.21% | 3,500 | $87.71 |
| Q2 2022 | -3,500 | Sold Out | 0 | $0.00 |
| Q4 2022 | +45,000 | New Buy | 45,000 | $90.72 |
| Q1 2023 | -34,800 | Reduce 77.33% | 10,200 | $92.00 |
| Q2 2023 | +672,756 | Add 6595.65% | 682,956 | $100.91 |
| Q3 2023 | +1.14 M | Add 167.55% | 1.83 M | $101.86 |
| Q4 2023 | -299,888 | Reduce 16.41% | 1.53 M | $100.97 |
| Q1 2024 | -581,499 | Reduce 38.07% | 945,876 | $96.73 |
| Q2 2024 | -166,195 | Reduce 17.57% | 779,681 | $106.46 |
| Q3 2024 | -114,662 | Reduce 14.71% | 665,019 | $115.02 |
| Q4 2024 | -87,118 | Reduce 13.10% | 577,901 | $97.31 |
| Q1 2025 | -185,750 | Reduce 32.14% | 392,151 | $111.48 |
| Q2 2025 | -39,456 | Reduce 10.06% | 352,695 | $121.01 |
| Q3 2025 | -21,663 | Reduce 6.14% | 331,032 | $128.24 |
Jeremy Grantham's Novartis Investment FAQs
Jeremy Grantham first purchased Novartis AG (NVS) in Q2 2018, acquiring 21,762 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Novartis AG (NVS) for 23 quarters since Q2 2018.
Jeremy Grantham's largest addition to Novartis AG (NVS) was in Q3 2023, adding 1,827,263 shares worth $186.13 M.
According to the latest 13F filing for Q3 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 331,032 shares of Novartis AG (NVS), valued at approximately $42.45 M.
As of the Q3 2025 filing, Novartis AG (NVS) represents approximately 0.12% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in Novartis AG (NVS) was 1,827,263 shares, as reported at the end of Q3 2023.